{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:39:13Z","timestamp":1791232753943,"version":"4.1.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2025,8,5]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">Dapagliflozin improved cardiometabolic outcomes following myocardial infarction in patients without prior type\u20102 diabetes (T2DM) in the DAPA\u2010MI (dapagliflozin in patients with myocardial infarction) trial. The effect of glycemic status and body mass index (BMI) post\u2013myocardial infarction requires elucidation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Participants with\n              <jats:styled-content style=\"fixed-case\" toggle=\"no\">T2DM<\/jats:styled-content>\n              diagnosis, without baseline\n              <jats:styled-content style=\"fixed-case\" toggle=\"no\">hemoglobin A1c<\/jats:styled-content>\n              , or not receiving any study medication, were excluded. Eligible participants were categorized, according to baseline\n              <jats:styled-content style=\"fixed-case\" toggle=\"no\">hemoglobin A1c<\/jats:styled-content>\n              , as normoglycemic (&lt;5.7% [39\u2009mmol\/mol]) or prediabetes (5.7 to &lt;6.5% [48\u2009mmol\/mol]) and according to baseline\n              <jats:styled-content style=\"fixed-case\" toggle=\"no\">BMI<\/jats:styled-content>\n              (&lt;25, 25 to &lt;30, and \u226530\u2009kg\/m\n              <jats:sup>2<\/jats:sup>\n              ). Hazard ratios (\n              <jats:styled-content style=\"fixed-case\" toggle=\"no\">HRs<\/jats:styled-content>\n              ) with 95%\n              <jats:styled-content style=\"fixed-case\" toggle=\"no\">CI<\/jats:styled-content>\n              s and 1\u2010year Kaplan\u2013Meier rates were determined for new\u2010onset\n              <jats:styled-content style=\"fixed-case\" toggle=\"no\">T2DM<\/jats:styled-content>\n              (investigator\u2010reported or\n              <jats:styled-content style=\"fixed-case\" toggle=\"no\">hemoglobin A1c<\/jats:styled-content>\n              \u22656.5%) and New York Heart Association symptom classification during follow\u2010up.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Of 4017 DAPA\u2010MI participants, 3425 were eligible. In 1926 with baseline normoglycemia, new\u2010onset T2DM occurred in 0.6% and 1.6% assigned to dapagliflozin and placebo, respectively (hazard ratio, 0.40 [95% CI, 0.15\u20131.03]); in 1499 with prediabetes at baseline, new\u2010onset T2DM occurred in 10.1% and 13.1%, respectively (hazard ratio, 0.74 [05% CI, 0.55\u20130.99];\n              <jats:italic toggle=\"no\">P<\/jats:italic>\n              interaction 0.23). One\u2010year absolute risk reduction for new\u2010onset T2DM was 8.1% in those with both prediabetes and BMI \u226530. Dapagliflozin reduced the occurrence of New York Heart Association class III\u2013IV symptoms, with greater effect in those with prediabetes versus normoglycemia (\n              <jats:italic toggle=\"no\">P<\/jats:italic>\n              interaction 0.009). One\u2010year absolute risk reduction for New York Heart Association class III\u2013IV symptoms was 10.0% in those with both prediabetes and BMI \u226530.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">Dapagliflozin reduced the occurrence of new\u2010onset T2DM following myocardial infarction, regardless of baseline hemoglobin A1c or BMI. Dapagliflozin provided greater reduction in heart failure symptom burden in those with prediabetes compared with normoglycemia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.124.040327","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T11:47:02Z","timestamp":1753789622000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Dapagliflozin on Cardiometabolic Outcomes After Acute Myocardial Infarction According to Baseline Glycemic Status and Body Mass Index: Subanalyses of the DAPA\u2010MI Trial"],"prefix":"10.1161","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-6229","authenticated-orcid":false,"given":"Robert F.","family":"Storey","sequence":"first","affiliation":[{"name":"University of Sheffield","place":["United Kingdom"]},{"name":"Sheffield Teaching Hospitals NHS Foundation Trust","place":["Sheffield, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Deanfield","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Sciences, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4413-9736","authenticated-orcid":false,"given":"Stefan","family":"James","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University","place":["Uppsala, Sweden"]},{"name":"Uppsala University","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1636-3725","authenticated-orcid":false,"given":"Ramzi A.","family":"Ajjan","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2152-4343","authenticated-orcid":false,"given":"Niclas","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-5766","authenticated-orcid":false,"given":"David","family":"Erlinge","sequence":"additional","affiliation":[{"name":"Lund University, Sk\u00e5ne University Hospital","place":["Lund, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2690-8319","authenticated-orcid":false,"given":"Mark","family":"de Belder","sequence":"additional","affiliation":[{"name":"National Institute for Cardiovascular Outcomes Research (NICOR), NHS Arden & GEM Commissioning Support Unit","place":["Leicester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4732-382X","authenticated-orcid":false,"given":"Chris P.","family":"Gale","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds","place":["United Kingdom"]},{"name":"Leeds Institute for Data Analytics, University of Leeds","place":["United Kingdom"]},{"name":"Leeds Teaching Hospitals NHS Trust","place":["Leeds, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-8892","authenticated-orcid":false,"given":"Azfar","family":"Zaman","sequence":"additional","affiliation":[{"name":"Cardiothoracic Centre, Freeman Hospital","place":["Newcastle upon Tyne, United Kingdom"]},{"name":"Translational and Clinical Research Institute, Newcastle University","place":["Newcastle upon Tyne, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-895X","authenticated-orcid":false,"given":"Robin","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, S\u00f6dersjukhuset","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8655-4044","authenticated-orcid":false,"given":"Linda","family":"Mellbin","sequence":"additional","affiliation":[{"name":"Karolinska Institutet","place":["Stockholm, Sweden"]},{"name":"Heart Vascular and Neuro Theme, Karolinska University Hospital","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-2613","authenticated-orcid":false,"given":"Kasper","family":"Andersen","sequence":"additional","affiliation":[{"name":"Uppsala University","place":["Sweden"]},{"name":"Uppsala University","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyun","family":"Jiang","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gaithersburg, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Johansson","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gothenburg, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Ridderstr\u00e5le","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gothenburg, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1696-9356","authenticated-orcid":false,"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gothenburg, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Parvaresh Rizi","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gothenburg, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-3921","authenticated-orcid":false,"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University","place":["Uppsala, Sweden"]},{"name":"Uppsala University","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6412-7989","authenticated-orcid":false,"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center","place":["Dallas"]},{"name":"Parkland Health System","place":["Dallas"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2260"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12081"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12054"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.069568"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2023.08.008"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300286"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09089-X"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30027-5"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2016-207402"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy066"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100693"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0059"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S002"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.1342"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.124.040327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T12:12:40Z","timestamp":1756296760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.124.040327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":20,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8,5]]}},"alternative-id":["10.1161\/JAHA.124.040327"],"URL":"https:\/\/doi.org\/10.1161\/jaha.124.040327","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"2024-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e040327"}}